Dyne Therapeutics Director Executes $1.9 Million Share Sale Under Pre-Set Trading Plan
Jason P. Rhodes, a director at Dyne Therapeutics, Inc. (NASDAQ: DYN), has completed a series of stock transactions totaling $1,936,341. The sale involved 106,723 shares of the biotechnology company's common stock and was carried out over a three-day period in early May 2026. These transactions were executed according to a Rule 10b5-1 trading plan t…